Surgery Partners heads into October with a curious split: short sellers are dug in at double-digit float levels, options traders are unusually bullish, and Wikipedia views just hit a near-record attention spike, all while the stock is down 9% on the week at $14.41.
Short interest has been sticky at an elevated level throughout September. It runs at 10.3% of free float, roughly 13.3 million shares, and has barely moved over the past month, up just 1.6%. The FINRA fortnightly print, settled through September 15, puts the count at 13.3 million shares with 6.4 days to cover. The ORTEX short score, currently at 61.9, has actually eased from 65 earlier in the month, reflecting slightly looser positioning rather than a fresh build. The borrow market is no help to would-be squeezers: availability is loose at 560%, more than five shares available to borrow for every one already shorted, and the cost to borrow has fallen 22% over the week to just 0.44%. That is a lending market with no stress in it whatsoever.
What makes this week's setup genuinely unusual is the options picture. Options traders are leaning long rather than defensively. The put/call ratio has dropped to 0.06, well below the 20-day average of 0.09 and 1.3 standard deviations below it. That is one of the most call-heavy readings SGRY has seen in the past year, with the 52-week PCR range running from 0.05 to 2.09. The divergence between that bullish options lean and the 10% short interest is the core tension of the current setup.
The Street is broadly constructive but with a clear ceiling on enthusiasm. RBC Capital reiterated its Outperform with a $19 target this week. TD Cowen held its Buy and $19 target last week. JP Morgan, the cautious outlier, nudged its Neutral target up to $15 from $14 earlier in September. With the stock at $14.41, that $15 target implies J.P. Morgan sees almost no room left. The mean target across the analyst community is $18.82, implying roughly 31% upside from here, but that consensus is anchored by a group that cut targets sharply in early March (TD Cowen from $28 to $20, UBS from $29 to $21). Bulls point to the outpatient care model, high-acuity procedure growth, and the Idaho Falls divestiture improving cash conversion. Bears flag the balance sheet leverage, the ongoing competition for clinical labor, and a margin profile that trails pure-play ASC peers. Valuation multiples give the bears some ammunition: PE has expanded sharply, up 24 points over the past 30 days to 48x, and EV/EBITDA has moved to 16x, up 2.6 turns over the same period. EPS surprise and momentum factor scores rank in the bottom decile of the universe, which means estimates have been coming down, not up.
The ownership structure helps explain why the stock has a floor. Bain Capital holds 38.5% of shares, with a Schedule 13D/A on the register. BCPE Seminole Holdings II Intermediate LP, also linked to the Bain complex, filed a 13D/A most recently in June 2025 reflecting a 23.5% stake. Those are activist-registered positions, as disclosed. Janus Henderson holds a further 10.7%. Together, the top three holders control nearly 60% of shares outstanding. King Street Capital has reduced its disclosed stake from 7.2% to 4.6% per its August 2026 filing, a notable trim worth watching. All 13D/G stakes are as-last-disclosed and positions can shift below the 5% threshold without a new filing.
One signal not in the analyst models is worth flagging. The ORTEX alt data layer recorded a Wikipedia and ORTEX page-view attention z-score of 8.1 as of September 28, an exceptionally high retail attention reading against the company's own 90-day history. This is an attention metric, not a revenue indicator, and carries no measured link to Surgery Partners' financial results. But a z-score of that magnitude, sitting well above the range typical for a mid-sized healthcare name, suggests something pulled eyes to the stock late in the quarter.
The next earnings date is November 10. After the August print, the stock fell 3.4% the following day and 7.5% over the subsequent five sessions. The print before that produced a 4.6% single-day loss and a 6.6% five-day decline. With 41 days to go, what to watch is whether short interest at 10% of float starts to move from its current flat trajectory, and whether the call-heavy options positioning holds or reverts as the print approaches.
See the live data behind this article on ORTEX.
Open SGRY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
